Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Haematologica|November 24, 2018
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2019
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)Karin Holmsten, Niels Viggo Jensen, Lene Sonne Mouritsen, et al.
Leukemia|September 26, 2021
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patientsLisa Blixt, Gordana Bogdanovic, Marcus Buggert, et al.
Breast Cancer Research and Treatment|January 4, 2024
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Ioannis Zerdes, Alexios Matikas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 TrialAlexios Matikas, Hemming Johansson, Per Grybäck, et al.
Journal of the National Cancer Institute|March 1, 2019
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in SituCarina Strell, Janna Paulsson, Shao-Bo Jin, et al.
JAMA|November 9, 2016
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical TrialTheodoros Foukakis, Gunter von Minckwitz, Nils-Olof Bengtsson, et al.
JAMA Oncology|June 24, 2021
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical TrialThomas Hatschek, Theodoros Foukakis, Judith Bjöhle, et al.
Nature Communications|April 8, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialAlexios Matikas, Evangelos Tzoras, Michail Sarafidis, et al.
Frontiers in Oncology|August 1, 2022
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS TrialMagnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Döbeln, et al.
Pageof 11